It is found that an antisense oligonucleotide comprising a sequence complementary to a sequence lying between position-95 and position-109, position-176 and position-192, position-467 and position-484, position-940 and position-954, position-1017 and position-1032, position-1102 and position-1116, position-1176 and position-1197, position-1222 and position-1236, position-1727 and position-1743, position-1858 and position-1873, position-1946 and position-1960, position-2294 and position-2308, position-2360 and position-2377, position-2449 and position-2469, position-2605 and position-2624, position-2689 and position-2703, position-2950 and position-2964, position-3424 and position-3438 or position-3591 and position-3605 in the sequence represented by SEQ ID NO: 2 has an excellent inhibitory activity on the expression of ACSL1. A pharmaceutical composition containing the antisense oligonucleotide for ACSL1 according to the present invention as an active ingredient is useful for the prevention or treatment of obesity or type-II diabetes.本發明發現了包含與下述序列互補之序列的反意寡核苷酸具有優異的ACSL1表現抑制活性:序列編號2之序列的95位至109位、176位至192位、467位至484位、940位至954位、1017位至1032位、1102位至1116位、1176位至1197位、1222位至1236位、1727位至1743位、1858位至1873位、1946位至1960位、2294位至2308位、2360位至2377位、2449位至2469位、2605位至2624位、2689位至2703位、2950位至2964位、3424位至3438位或者是3591位至3605位之序列。本發明之含有針對ACSL1之反意寡核苷酸作為有效成分的醫藥組成物對於肥胖症或者是第II型糖尿病之預防或者是治療均甚有用。
